Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
    Meeting Abstract

    Li, B. T.; Lee, K. W.; Pegram, M.; Sharma, M. R.; Lee, J.; Spira, A. I.; Kang, Y. K.; Moore, K. N.; Rasco, D.; Hanna, G. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations
    Meeting Abstract

    Pelster, M. S.; Yaeger, R.; Klempner, S. J.; Ou, S. H. I.; Spira, A. I.; Jänne, P. A.; Uboha, N. V.; Gaffar, Y. A.; Newman, G.; Paweletz, C. P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER
    Meeting Abstract

    Strickler, J. H.; Cercek, A.; Ng, K.; Siena, S.; André, T.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J.; Coveler, A. L.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials
    Meeting Abstract

    Taieb, J.; Pederson, L.; Sinicrope, F. A.; Lonardi, S.; Alberts, S.; George, T.; Saltz, L.; Yothers, G.; Goldberg, R.; Kerr, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
    Meeting Abstract

    Weiser, M.; Shi, Q.; Chang, G. J.; Hakki, L.; Goldberg, J.; Auer, R.; Gollub, M.; Saltz, L.; Musher, B. L.; Al Baghdadi, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Imlunestrant with or without everolimus or alpelisib, in ER+, HER2-advanced breast cancer (aBC): Results from the phase Ia/b EMBER
    Meeting Abstract

    Jhaveri, K.; Jeselsohn, R.; Ma, C. X.; Lim, E.; Yonemori, K.; Hamilton, E. P.; Harnden, K.; Im, S. A.; Beck, T.; Sammons, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Meeting Abstract

    Tsurutani, J.; Jacot, W.; Yamashita, T.; Riaz, F.; Yerushalmi, R.; Im, S. A.; Niikura, N.; Halser-Strub, U.; Cortés, J.; Wennstig, A. K.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (Saci) in a single academic institution
    Meeting Abstract

    Walsh, E. M.; Klar, M.; Abuhadra, N.; Robson, M.; Drago, J.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma
    Meeting Abstract

    Blumenthal, D.; Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Peters, K.; Clarke, J.; Mendez, J.; Welsh, L.; Mason, W.; Hottinger, A. F.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
    Meeting Abstract

    Goetz, M. P.; Turner, N.; Sasano, H.; Arteaga, C.; Chandarlapaty, S.; Loi, S.; Reis-Filho, J. S.; Kreipe, H.; Harbeck, N.; Fasching, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save